New combo aims to stop ovarian Cancer's return

NCT ID NCT07472140

Recruiting now Disease control Sponsor: N.N. Alexandrov National Cancer Centre Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a PARP inhibitor combined with bevacizumab (Avastin) can delay cancer recurrence in people with advanced ovarian, fallopian-tube, or primary peritoneal cancer that has a specific DNA repair defect (HRD). About 120 participants will receive chemotherapy plus the combo as maintenance therapy. The goal is to see if this approach extends the time without cancer returning.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PARP inhibitor plus bevacizumab (Avastin)
What this could lead to: If successful, this combination could help keep advanced ovarian cancer from coming back for a longer time, offering better disease control.
What could go wrong: This is a Phase 2/3 trial, so results are not yet proven. The drugs can cause side effects like high blood pressure, fatigue, and blood problems. Not all patients will benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube neoplasm ovarian cancer primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FALLOPIAN TUBE CANCERS OVARIAN CANCER PRIMARY PERITONEAL CANCER

Contacts and locations

Locations

N.N. Alexandrov National Caner Centre
RECRUITING

Minsk, Lesnoy, 223040, Belarus

More trials for these conditions

Other studies related to the condition(s) this trial covers.